Close Menu

NEW YORK – Cambridge, Massachusetts-based Ymir Genomics said on Wednesday that it has signed a licensing agreement and filed a joint patent application with the Oregon Health & Science University's Knight Cancer Institute that aims to protect and promote newly discovered urinary biomarkers for cirrhosis or hepatocellular carcinoma (HCC).

Ymir and OHSU will share in any value created by the biomarkers and will jointly publish and validate the biomarkers in a large-scale multi-center study.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A Harvard-led team reprogrammed DNA methylation patterns of mice with eye problems to restore their sight, AFP reports.

A man in India is suing the Serum Institute of India, saying that he suffered serious side effects from a vaccine it is testing, but the institute has rejected those claims, the Economic Times reports.

The New York Times reports Moderna is planning a clinical trial of its SARS-CoV-2 vaccine in children.

In Nature this week: Readfish tool for targeted nanopore sequencing, genomic diversity of barley and wheat, and more.